Will immune checkpoint inhibitors become the new standard of care for urothelial cancer?
Sequencing treatment options in breast cancer
Promising biomarkers to select patients for checkpoint inhibitor therapy in melanoma
Interesting topics presented at ESMO 2017
Managing the side effects of immunotherapy: a vital consideration